Fibric acid derivatives for high cholesterol

References

Citations

1. Grundy SM, et al. (2001). Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA, 285(19): 2486–2497.

2. Rubins HB, et al. (1999). Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. New England Journal of Medicine, 341(6): 410–418.

3. Steiner G, et al. (2001). Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet, 357(9260): 905–910.

4. Keech A, et al. (2005). Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet, 366(9500): 1849–61.

5. Frick MH, et al. (1987). Helsinki heart study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. New England Journal of Medicine, 317(20): 1237–1245.

6. Bellosta S, et al. (2004). Safety of statins: Focus on clinical pharmacokinetics and drug interactions. Circulation, 109(23, Suppl 1): III50–III57.

Author:	Ralph Poore	Last Updated: July 20, 2006
Medical Review:	Caroline S. Rhoads, MD - Internal Medicine Neil J. Stone, MD, FACC, FACP - Internal Medicine, Cardiology
© 1995-2008 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.This information does not replace the advice of a doctor. Healthwise disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.